Showing results (1011-1020 of 1,096) with videos related to
Sort By:
Pageof 110
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 17, 2023
Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology GroupDaniel Rivera, Wei Cui, Juehua Gao, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 27, 2015
Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapyRajesh R Singh, Paari Murugan, Lalit R Patel, et al.British Journal of Haematology|June 28, 2019
Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patientsBoyu Hu, Keyur P Patel, Hsiang-Chun Chen, et al.Journal of Medicinal Chemistry|April 21, 2009
Synthesis and antiviral activity of 7-benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV integrase inhibitorsEric E Boros, Cynthia E Edwards, Scott A Foster, et al.Blood|May 16, 2012
Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year resultsIssa F Khouri, Rima M Saliba, William D Erwin, et al.American Journal of Hematology|April 10, 2019
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk diseaseAndrés E Quesada, Mark J Routbort, Courtney D DiNardo, et al.Cancer|March 21, 2014
Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium ProgramChi Young Ok, Zijun Y Xu-Monette, Alexandar Tzankov, et al.Journal of Medicinal Chemistry|July 27, 2026
Discovery of a Potent, Orally Bioavailable Small-Molecule Inhibitor of Wildtype KIT with Exceptionally High Kinome SelectivityKaren Y Chen, Shiwei Qu, Xuelei Yan, et al.Clinical Lymphoma, Myeloma & Leukemia|October 27, 2018
Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation TherapyAlison K Yoder, Jillian R Gunther, Sarah A Milgrom, et al.The Lancet. Oncology|December 8, 2015
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trialMichael L Wang, Hun Lee, Hubert Chuang, et al.Pageof 110